Alembic Pharma Q1 Review: Dolat Capital Maintains 'Add', Revises Target Price — Here's Why

Dolat Capital maintains ‘Accumulate’ rating on Alembic Pharma and revises target price.

Alembic Pharma’s Q1 FY26 sales and Ebitda came in line with estimates

(Photo: PxHere)

Alembic Pharma’s Q1 FY26 sales and Ebitda came in line with estimates, while PAT came below due to lower-than-expected other income and higher than expected depreciation and tax rate.

NDTV Profit’s special research section collates quality and in-depth equity and economy research reports from across India’s top brokerages, asset managers and research agencies. These reports offer NDTV Profit’s subscribers an opportunity to expand their understanding of companies, sectors and the economy.

Dolat Capital Report

We expect Alembic Pharmaceutical Ltd.'s recovery in earnings growth over FY26E-FY27E, aided by ramp-up in new product launches offsetting US price erosion and recovery in domestic and RoW markets.

We maintain our ‘Accumulate’ rating with revised target price of Rs 1,040 at 22x FY27E P/E.

Key risks: Adverse pricing pressure in the US, currency movements and regulatory issues at any of its facilities.

Click on the attachment to read the full report:

Dolat Capital Alembic Pharma (Q1FY26 Result Update)_05-Aug-2025.pdf
Read Document

Also Read: Adani Ports Q1 Results Review — Well Positioned For Further Expansion Says Motilal Oswal Maintaining 'Buy'

DISCLAIMER

This report is authored by an external party. NDTV Profit does not vouch for the accuracy of its contents nor is responsible for them in any way. The contents of this section do not constitute investment advice. For that you must always consult an expert based on your individual needs. The views expressed in the report are that of the author entity and do not represent the views of NDTV Profit.

Users have no license to copy, modify, or distribute the content without permission of the Original Owner.

Watch LIVE TV, Get Stock Market Updates, Top Business, IPO and Latest News on NDTV Profit.
GET REGULAR UPDATES